Rheumatic Heart Disease (RHD) is a chronic, progressive condition arising from rheumatic fever, an inflammatory response to untreated Group A Streptococcus (GAS) pharyngitis. While antibiotic prophylaxis has dramatically reduced its incidence in developed nations, RHD remains a significant cause of cardiovascular morbidity and mortality worldwide, particularly in low-resource settings. The pathophysiological cascade initiating RHD is a complex interplay between host immune response and bacterial factors, ultimately leading to permanent damage to heart valves. Understanding this process is crucial for effective prevention and management strategies.
The initial trigger for RHD is a GAS infection, most commonly streptococcal pharyngitis. The bacteria possess surface antigens, such as M protein and streptococcal pyrogenic exotoxins (SPEs), that are structurally similar to host tissues, particularly cardiac myosin and valvular components. This molecular mimicry is a key factor in the development of RHD. Following infection, the host mounts an immune response, producing antibodies against GAS. However, due to molecular mimicry, these antibodies also cross-react with self-antigens in the heart. This autoimmune phenomenon drives the inflammatory cascade characteristic of rheumatic fever.
Acute rheumatic fever (ARF) manifests as a systemic inflammatory syndrome affecting various tissues, including the heart, joints, brain, and skin. The cardiac manifestations of ARF, collectively termed rheumatic carditis, are the most serious and can lead to permanent valve damage. In the acute phase, inflammation of the endocardium, myocardium, and pericardium occurs. Microscopic examination reveals Aschoff bodies, which are characteristic inflammatory lesions containing activated macrophages (Anitschkow cells), lymphocytes, and plasma cells, often found in the interstitial connective tissue of the heart. These inflammatory infiltrates lead to edema, fibrinoid degeneration, and eventual fibrosis.
The valvular endocardium is particularly susceptible to damage. Initially, small vegetations, known as "verrucae," form along the valve leaflets, primarily on the closure lines. These vegetations are composed of fibrin, platelets, and inflammatory cells. The inflammatory process extends to the chordae tendineae and papillary muscles, causing edema, inflammation, and fibrosis. Over time, these changes lead to shortening, thickening, and fusion of the chordae tendineae. The valve leaflets themselves become thickened, rigid, and distorted. This distortion impairs normal valve function, leading to either regurgitation (incompetence) or stenosis (narrowing) of the affected valves. The mitral valve is most commonly affected, followed by the aortic valve. Tricuspid and pulmonary valves are less frequently involved.
The chronic phase of RHD is characterized by progressive fibrosis and calcification of the damaged valves. The initial inflammatory lesions resolve, but the resulting scarring and deformities are permanent. The continuous hemodynamic stress on the already damaged valves exacerbates the damage over years or decades. Stenosis typically results from fusion of the commissures and thickening of the valve leaflets, restricting blood flow. Regurgitation occurs due to leaflet retraction, perforation, or chordal rupture, allowing blood to flow backward. These valvular abnormalities place a significant burden on the heart, leading to chamber dilation, hypertrophy, and eventually heart failure. Arrhythmias, such as atrial fibrillation, are also common complications due to atrial enlargement and fibrosis.
The global burden of RHD is substantial, disproportionately affecting populations with limited access to healthcare and antibiotic treatment for streptococcal infections. Recurrent episodes of ARF, often due to inadequate secondary prophylaxis, can accelerate valve damage and lead to earlier onset of severe RHD. Early diagnosis and treatment of GAS pharyngitis are the cornerstones of prevention. For individuals with a history of ARF or established RHD, long-term antibiotic prophylaxis is essential to prevent recurrent GAS infections and further valvular damage. Echocardiography plays a vital role in diagnosing and monitoring valvular lesions, guiding surgical intervention when necessary.
In summary, Rheumatic Heart Disease is a sequela of an autoimmune response triggered by Group A Streptococcus. Molecular mimicry between bacterial antigens and host cardiac tissues initiates an inflammatory process that, if untreated or recurrent, leads to chronic valvular damage. The characteristic lesions of rheumatic fever, including Aschoff bodies and valvular verrucae, evolve into permanent fibrotic and calcific deformities, resulting in valvular stenosis and/or regurgitation. This progressive cardiac dysfunction underscores the importance of primary prevention through prompt treatment of streptococcal pharyngitis and secondary prevention via long-term antibiotic prophylaxis to mitigate the devastating global impact of RHD.